Scancell Holdings PLC
LSE:SCLP

Watchlist Manager
Scancell Holdings PLC Logo
Scancell Holdings PLC
LSE:SCLP
Watchlist
Price: 10.2 GBX 3.03% Market Closed
Market Cap: 105.9m GBX

Scancell Holdings PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Scancell Holdings PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Scancell Holdings PLC
LSE:SCLP
EPS (Diluted)
ÂŁ0
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
EPS (Diluted)
-$2
CAGR 3-Years
26%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
EPS (Diluted)
-$3
CAGR 3-Years
-2%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
EPS (Diluted)
-ÂŁ1
CAGR 3-Years
31%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
EPS (Diluted)
ÂŁ0
CAGR 3-Years
-23%
CAGR 5-Years
-12%
CAGR 10-Years
-8%
Oxford BioMedica PLC
LSE:OXB
EPS (Diluted)
ÂŁ0
CAGR 3-Years
-10%
CAGR 5-Years
-17%
CAGR 10-Years
-6%
No Stocks Found

Scancell Holdings PLC
Glance View

Market Cap
105.8m GBX
Industry
Biotechnology

Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. The company is headquartered in Oxford, Oxfordshire and currently employs 25 full-time employees. The company went IPO on 2010-07-30. The firm is focused on developing immunotherapies for the treatment of cancer and infectious disease. The Company’s technology includes ImmunoBody, Moditope, and AvidiMab, Its product pipeline includes SCIB1, SCIB2, Modi-1, Modi-2 and SCOV1& SCOV2 (COVIDITY). Its lead ImmunoBody cancer vaccine, SCIB1, is developed for the treatment of patients with metastatic melanoma. SCIB1 consists of SCIB1-001 and SCIB1-002. Its SCIB2 is the second cancer vaccine based on the ImmunoBody technology. SCIB2 vaccine is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer (NSCLC). Modi-1 is based on Moditope platform, which is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. Modi-2 targets homocitrullinated cancer antigens, to address different cancer indications to Modi-1, including tumors.

SCLP Intrinsic Value
3.1 GBX
Overvaluation 70%
Intrinsic Value
Price

See Also

What is Scancell Holdings PLC's EPS (Diluted)?
EPS (Diluted)
-0 GBP

Based on the financial report for Apr 30, 2025, Scancell Holdings PLC's EPS (Diluted) amounts to -0 GBP.

What is Scancell Holdings PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
0%

Over the last year, the EPS (Diluted) growth was 0%.

Back to Top